ATA 200
Alternative Names: ATA-200; GNT-0007; LGMD-R5/LGMD2C gene therapy - Atamyo TherapeuticsLatest Information Update: 21 Jan 2025
Price :
$50 *
At a glance
- Originator Atamyo Therapeutics
- Class Gene therapies
- Mechanism of Action Gene transference; Sarcoglycan replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Limb girdle muscular dystrophies
Most Recent Events
- 12 Nov 2024 ATA 200 receives Rare Pediatric Disease Designation for Limb-girdle muscular dystrophies in USA
- 12 Nov 2024 US FDA approves IND application for ATA-200 in Limb-girdle muscular dystrophy
- 04 Sep 2024 Atamyo Therapeutics announces intention to file an IND application to the US FDA for Limb-girdle muscular dystrophy Type 2C/R5 (LGMD2C/R5)